SCHEMBL1873337

SCHEMBL1873337

CS(=O)(=O)OC1CCCC1Oc1ccc(Br)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.35
PTGS1 P23219 2/20 0.34
PTGS2 P35354 2/20 0.34
ENPP3 O14638 1/20 0.33
ENPP1 P22413 1/20 0.33
PARP15 Q460N3 1/20 0.32
PARP10 Q53GL7 1/20 0.32
FPR2 P25090 2/20 0.32
PROKR1 Q8TCW9 2/20 0.32
GPR119 Q8TDV5 1/20 0.32
CYP2D6 P10635 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
SCN2B O60939 1/20 0.32
SCN1A P35498 1/20 0.32
SCN1B Q07699 1/20 0.32
SCN9A Q15858 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1873334 1.00 MCHR1 (0.35) MCHR1PTGS1PTGS2ENPP3ENPP1
SCHEMBL1872980 0.80 CA1 (0.40) ENPP3ENPP1HRH3CA12CA1
SCHEMBL1872982 0.80 CA1 (0.40) ENPP3ENPP1HRH3CA12CA1
SCHEMBL1872984 0.80 CA1 (0.40) ENPP3ENPP1HRH3CA12CA1
SCHEMBL1875894 0.79 PTGS1 (0.39) MCHR1PTGS1PTGS2PARP15PARP10
SCHEMBL1875896 0.79 PTGS1 (0.39) MCHR1PTGS1PTGS2PARP15PARP10
SCHEMBL1878373 0.77 ENPP3 (0.40) ENPP3ENPP1CA12CA1CA2
SCHEMBL1878371 0.77 ENPP3 (0.40) ENPP3ENPP1CA12CA1CA2
SCHEMBL1874389 0.76 NPY1R (0.47) MCHR1PTGS1PTGS2PARP15PARP10
SCHEMBL1874392 0.76 NPY1R (0.47) MCHR1PTGS1PTGS2PARP15PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051917-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF BIOGEN MA INC (US) 2024-02-15 US disclosed
US-20190100491-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. 2019-04-04 US disclosed
US-20170247360-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF BIOGEN MA INC. 2017-08-31 US disclosed
US-20160272625-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. (US) 2016-09-22 US disclosed
US-20140323502-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF BIOGEN MA INC. 2014-10-30 US disclosed
EP-2445883-B1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER (US) 2014-08-13 EP disclosed
US-20120322823-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. 2012-12-20 US disclosed
US-8278457-B2 Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof PFIZER INC. (US) 2012-10-02 US disclosed
US-20110105533-A1 Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof PFIZER INC. 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105533-A1 Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof STS, SULT2A1, SULT1A1 MCHR1 3704/4885PTGS1 730/4885PTGS2 788/4885
US-20240051917-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 MCHR1 3704/4885PTGS1 730/4885PTGS2 788/4885
US-20120322823-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 MCHR1 3704/4885PTGS1 730/4885PTGS2 788/4885
US-20140323502-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 MCHR1 3704/4885PTGS1 730/4885PTGS2 788/4885
US-20160272625-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 MCHR1 3704/4885PTGS1 730/4885PTGS2 788/4885
US-20170247360-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 MCHR1 3704/4885PTGS1 730/4885PTGS2 788/4885
US-20190100491-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 MCHR1 3704/4885PTGS1 730/4885PTGS2 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.